JP5946218B2 - Ｊｃウイルス抗体に対するアッセイ - Google Patents

Ｊｃウイルス抗体に対するアッセイ Download PDF

Info

Publication number
JP5946218B2
JP5946218B2 JP2012548227A JP2012548227A JP5946218B2 JP 5946218 B2 JP5946218 B2 JP 5946218B2 JP 2012548227 A JP2012548227 A JP 2012548227A JP 2012548227 A JP2012548227 A JP 2012548227A JP 5946218 B2 JP5946218 B2 JP 5946218B2
Authority
JP
Japan
Prior art keywords
hpvlp
jcv
subject
sample
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012548227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516633A5 (enExample
JP2013516633A (ja
Inventor
レオニード ゴーリック，
レオニード ゴーリック，
ケニス ジェイ． シモン，
ケニス ジェイ． シモン，
ミーナ サブラマンヤム，
ミーナ サブラマンヤム，
ミア マリー ラッシ，
ミア マリー ラッシ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5946218(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2013516633A publication Critical patent/JP2013516633A/ja
Publication of JP2013516633A5 publication Critical patent/JP2013516633A5/ja
Application granted granted Critical
Publication of JP5946218B2 publication Critical patent/JP5946218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012548227A 2010-01-11 2011-01-11 Ｊｃウイルス抗体に対するアッセイ Active JP5946218B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29404810P 2010-01-11 2010-01-11
US61/294,048 2010-01-11
US31619310P 2010-03-22 2010-03-22
US61/316,193 2010-03-22
PCT/US2011/020832 WO2011085369A1 (en) 2010-01-11 2011-01-11 Assay for jc virus antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015246985A Division JP2016040557A (ja) 2010-01-11 2015-12-18 Ｊｃウイルス抗体に対するアッセイ

Publications (3)

Publication Number Publication Date
JP2013516633A JP2013516633A (ja) 2013-05-13
JP2013516633A5 JP2013516633A5 (enExample) 2014-02-27
JP5946218B2 true JP5946218B2 (ja) 2016-07-05

Family

ID=44305841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012548227A Active JP5946218B2 (ja) 2010-01-11 2011-01-11 Ｊｃウイルス抗体に対するアッセイ
JP2015246985A Withdrawn JP2016040557A (ja) 2010-01-11 2015-12-18 Ｊｃウイルス抗体に対するアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015246985A Withdrawn JP2016040557A (ja) 2010-01-11 2015-12-18 Ｊｃウイルス抗体に対するアッセイ

Country Status (27)

Country Link
US (2) US9316641B2 (enExample)
EP (4) EP2524060B1 (enExample)
JP (2) JP5946218B2 (enExample)
KR (1) KR101877576B1 (enExample)
CN (1) CN102906278A (enExample)
AU (1) AU2011203815B2 (enExample)
BR (1) BR112012017014B1 (enExample)
CA (1) CA2784137A1 (enExample)
CY (2) CY1119972T1 (enExample)
DK (3) DK4152004T3 (enExample)
ES (3) ES2930469T3 (enExample)
FI (2) FI4152004T3 (enExample)
HR (3) HRP20180356T1 (enExample)
HU (3) HUE036183T2 (enExample)
IN (1) IN2012DN06139A (enExample)
LT (3) LT4152004T (enExample)
ME (1) ME03026B (enExample)
MX (1) MX341991B (enExample)
NO (1) NO2524060T3 (enExample)
NZ (1) NZ600681A (enExample)
PL (3) PL4152004T3 (enExample)
PT (3) PT3339865T (enExample)
RS (3) RS66509B1 (enExample)
SG (2) SG10201500079YA (enExample)
SI (3) SI3339865T1 (enExample)
SM (3) SMT201800148T1 (enExample)
WO (1) WO2011085369A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124350B2 (en) 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
US11287423B2 (en) * 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HUE061244T2 (hu) * 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere
US20150065367A1 (en) * 2011-12-12 2015-03-05 Janssen Diagnostics Bvba Polyomavirus peptide sequences
US20130273549A1 (en) * 2012-04-16 2013-10-17 Board Of Regents, The University Of Texas System Detection of extracellular jcv micrornas
US9631243B2 (en) 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
EP3517545A1 (en) * 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9949671B2 (en) 2013-03-13 2018-04-24 Orthoaccel Technologies, Inc. Diagnostic mouthpieces
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
ES2818823T3 (es) * 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
WO2019169317A1 (en) * 2018-03-02 2019-09-06 Stueve Olaf Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
EP0646179A4 (en) 1992-02-04 1996-10-02 Quidel Corp PROCESS FOR SIMPLIFIED EXTRACTION OF BACTERIAL ANTIGENS USING DEHYDRATE REAGENTS.
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
EP0630475B1 (en) 1992-03-10 2000-09-06 Quidel Corporation Red blood cell separation means for specific binding assays
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
EP1232392B2 (de) 1999-10-12 2014-04-02 Oxoid (Ely) Limited Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
AU783110B2 (en) 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
WO2001075449A1 (fr) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
AU1038402A (en) 2000-10-17 2002-04-29 Besst Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
JP4264348B2 (ja) 2001-08-20 2009-05-13 プロテオム システムズ リミテッド 診断検査方法および装置
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CA2490284C (en) 2002-06-21 2013-10-22 Mckesson Information Solutions Llc Closed loop medication use system and method
WO2005052567A1 (en) 2003-11-24 2005-06-09 Biogen Idec Ma Inc. Methods for detecting half-antibodies using chip-based gel electrophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
CA2573245C (en) 2004-07-08 2013-10-01 Elan Pharmaceuticals, Inc. Multivalent vla-4 antagonists comprising polymer moieties
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
NZ581497A (en) 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
US8124350B2 (en) 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
EA017110B1 (ru) 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US7838583B2 (en) * 2006-06-30 2010-11-23 Sumitomo Rubber Industries, Ltd. Rubber composition for cap tread and pneumatic tire having cap tread using same
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
AU2010210979B2 (en) * 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
US9354233B2 (en) 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
BR112012017014B1 (pt) * 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
HUE061244T2 (hu) 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere

Also Published As

Publication number Publication date
FI3339865T5 (fi) 2023-04-15
IN2012DN06139A (enExample) 2015-09-18
US20130022961A1 (en) 2013-01-24
LT4152004T (lt) 2025-02-25
ES2664173T3 (es) 2018-04-18
HRP20180356T1 (hr) 2018-04-06
PT4152004T (pt) 2025-02-18
LT3339865T (lt) 2022-12-12
MX341991B (es) 2016-09-09
SI4152004T1 (sl) 2025-04-30
CY1126069T1 (el) 2023-11-15
KR101877576B1 (ko) 2018-07-12
SI3339865T1 (sl) 2023-01-31
DK3339865T5 (da) 2023-03-20
DK2524060T3 (en) 2018-03-12
NO2524060T3 (enExample) 2018-04-28
WO2011085369A1 (en) 2011-07-14
EP4152004B9 (en) 2025-04-09
HUE070903T2 (hu) 2025-07-28
PL3339865T3 (pl) 2022-12-19
EP4524571A3 (en) 2025-06-11
MX2012007660A (es) 2012-07-25
ES3012733T3 (en) 2025-04-10
CY1119972T1 (el) 2018-12-12
US9316641B2 (en) 2016-04-19
NZ600681A (en) 2014-10-31
US20160187337A1 (en) 2016-06-30
SMT201800148T1 (it) 2018-05-02
PL2524060T3 (pl) 2018-05-30
EP3339865B1 (en) 2022-08-24
FI4152004T3 (fi) 2025-02-21
KR20120112621A (ko) 2012-10-11
RS56977B1 (sr) 2018-05-31
HRP20250210T1 (hr) 2025-04-11
PL4152004T3 (pl) 2025-03-24
SG181653A1 (en) 2012-07-30
SMT202200445T1 (it) 2023-01-13
DK4152004T3 (da) 2025-02-24
HRP20221390T1 (hr) 2023-01-06
JP2013516633A (ja) 2013-05-13
DK3339865T3 (da) 2022-11-28
BR112012017014A8 (pt) 2018-06-05
EP4152004B1 (en) 2024-11-20
CA2784137A1 (en) 2011-07-14
ME03026B (me) 2018-10-20
BR112012017014B1 (pt) 2021-07-20
EP4524571A2 (en) 2025-03-19
PT2524060T (pt) 2018-03-28
HUE060312T2 (hu) 2023-02-28
HUE036183T2 (hu) 2018-06-28
EP2524060B1 (en) 2017-11-29
AU2011203815B2 (en) 2015-11-26
ES2930469T3 (es) 2022-12-14
PT3339865T (pt) 2022-11-22
RS66509B1 (sr) 2025-03-31
AU2011203815A1 (en) 2012-07-05
SMT202500065T1 (it) 2025-03-12
EP2524060A1 (en) 2012-11-21
JP2016040557A (ja) 2016-03-24
EP3339865B9 (en) 2022-12-14
BR112012017014A2 (pt) 2016-04-05
RS63744B1 (sr) 2022-12-30
EP2524060A4 (en) 2013-10-09
SI2524060T1 (en) 2018-05-31
HK1255318A1 (en) 2019-08-16
SG10201500079YA (en) 2015-03-30
EP4152004A1 (en) 2023-03-22
US10444234B2 (en) 2019-10-15
CN102906278A (zh) 2013-01-30
LT2524060T (lt) 2018-03-26
FI3339865T3 (enExample) 2022-11-30
EP3339865A1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
JP2016040557A (ja) Ｊｃウイルス抗体に対するアッセイ
Nguyen et al. Serologic evidence of frequent human infection with WU and KI polyomaviruses
CN105866426B (zh) 用于检测补体结合性抗体的方法和组合物
ES2729945T3 (es) Procedimiento para valorar el riesgo de LMP
Meyer et al. Serological assays for emerging coronaviruses: challenges and pitfalls
CN105829892B (zh) Csfv抗体的改进的诊断测试
US11287423B2 (en) Assay for JC virus antibodies
HK40123180A (en) Assay for jc virus antibodies
HK40088791A (en) Assay for jc virus antibodies
HK40088791B (en) Assay for jc virus antibodies
HK1255318B (en) Assay for jc virus antibodies
HK1177234B (en) Assay for jc virus antibodies
HK1177234A (en) Assay for jc virus antibodies
Corcoran et al. Improved detection of acute parvovirus B19 infection by immunoglobulin M EIA in combination with a novel antigen EIA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160530

R150 Certificate of patent or registration of utility model

Ref document number: 5946218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250